# SGP (SpyGlass Pharma, Inc.) - SEC EDGAR Financial Statements

> SpyGlass Pharma, Inc. reported $226.3M in total assets and a net loss of $70.49M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/SGP
- Markdown: https://convexityos.com/fundamentals/SGP.md
- SEC CIK: 0001778922
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:29 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001778922&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$77.25M | Operating profit |
| Net Income | FY 2025 | -$70.49M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$2.11 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$59.23M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $208.7M | Total debt: $1.61M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Research & Development | $29.18M | $19.98M |
| Total Operating Expenses | $41.45M | $27.06M |
| **Operating Income** | -$41.45M | -$27.06M |
| **EBITDA** | -$40.84M | -$26.79M |
| Interest Income | $3.11M | $1.32M |
| Income Before Tax | -$39.87M | -$29.16M |
| Income Tax Expense | $0 | $0 |
| **Net Income** | -$39.87M | -$29.16M |
| Basic EPS | -$103.10 | -$93.52 |
| **Diluted EPS** | -$103.10 | -$93.52 |
| Basic Shares Outstanding | 386.7K | 311.9K |
| Diluted Shares Outstanding | 386.7K | 311.9K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $10.03M | $10.94M | $8.54M | $7.71M | $8.09M | $7.33M | $6.05M |
| Total Operating Expenses | $26.25M | $21.97M | $15.41M | $13.63M | $11.10M | $9.30M | $7.42M |
| **Operating Income** | -$26.25M | -$21.97M | -$15.41M | -$13.63M | -$11.10M | -$9.30M | -$7.42M |
| **EBITDA** | -$25.96M | -$21.63M | -$15.09M | -$13.41M | -$10.96M | -$9.16M | -$7.30M |
| Interest Income | $1.99M | $2.10M | $1.59M | $1.07M | $1.28M | $622K | $126K |
| Income Before Tax | -$24.25M | -$19.86M | -$13.82M | -$12.55M | -$9.82M | -$8.68M | -$8.82M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$24.25M | -$19.86M | -$13.82M | -$12.55M | -$9.82M | -$8.68M | -$8.82M |
| Basic EPS | -$0.73 | -$0.59 | -$0.69 | -- | -$4.53 | -$3.81 | -$3.96 |
| **Diluted EPS** | -$0.73 | -$0.59 | -$0.69 | -- | -$4.53 | -$3.81 | -$3.96 |
| Basic Shares Outstanding | 33.5M | 33.4M | 19.9M | -- | 2.2M | 2.3M | 2.2M |
| Diluted Shares Outstanding | 33.5M | 33.4M | 19.9M | -- | 2.2M | 2.3M | 2.2M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $96.36M | $16.27M |
| **Cash & Short-Term Investments** | $96.36M | $16.27M |
| **Total Current Assets** | $108.8M | $17.41M |
| Property, Plant & Equipment, Net | $2.34M | $2.17M |
| Other Non-Current Assets | $492K | $453K |
| **Total Non-Current Assets** | $7.10M | $5.91M |
| **Total Assets** | $115.9M | $23.32M |
| Accounts Payable | $2.70M | $1.98M |
| Other Current Liabilities | $3.71M | $672K |
| **Total Current Liabilities** | $8.58M | $7.79M |
| **Total Non-Current Liabilities** | $1.58M | $3.46M |
| **Total Liabilities** | $10.17M | $11.25M |
| **Total Debt (incl. Leases)** | $1.57M | $3.90M |
| Common Stock | $0 | $0 |
| Retained Earnings | -$104.7M | -$64.86M |
| **Total Stockholders' Equity** | -$98.84M | -$60.47M |
| Total Equity | -$98.84M | -$60.47M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $208.7M | $223.1M | $238.9M | $96.36M | $16.27M |
| **Cash & Short-Term Investments** | $208.7M | $223.1M | $238.9M | $96.36M | $16.27M |
| **Total Current Assets** | $217.9M | $236.5M | $253.4M | $108.8M | $17.41M |
| Property, Plant & Equipment, Net | $6.34M | $4.79M | $2.75M | $2.34M | $2.17M |
| Other Non-Current Assets | $689K | $759K | $789K | $492K | $453K |
| **Total Non-Current Assets** | $8.43M | $6.97M | $5.02M | $7.10M | $5.91M |
| **Total Assets** | $226.3M | $243.4M | $258.4M | $115.9M | $23.32M |
| Accounts Payable | $5.65M | $4.16M | $3.51M | $2.70M | $1.98M |
| Other Current Liabilities | $6.14M | $3.56M | $2.27M | $3.71M | $672K |
| **Total Current Liabilities** | $14.30M | $9.44M | $6.67M | $8.58M | $7.79M |
| **Total Non-Current Liabilities** | $1.61M | $1.63M | $1.61M | $1.58M | $3.46M |
| **Total Liabilities** | $15.91M | $11.07M | $8.27M | $10.17M | $11.25M |
| **Total Debt (incl. Leases)** | $1.61M | $1.63M | $1.61M | $1.57M | $3.90M |
| Common Stock | $0 | $0 | $0 | $0 | $0 |
| Retained Earnings | -$162.7M | -$138.4M | -$118.5M | -$104.7M | -$64.86M |
| **Total Stockholders' Equity** | $210.4M | $232.4M | $250.1M | -$98.84M | -$60.47M |
| Total Equity | $210.4M | $232.4M | $250.1M | -$98.84M | -$60.47M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Net Income | -$39.87M | -$29.16M |
| Depreciation & Amortization | $612K | $271K |
| Stock-Based Compensation | $2.79M | $1.49M |
| Change in Payables | $549K | $1.34M |
| **Operating Cash Flow** | -$32.70M | -$22.03M |
| Capital Expenditure | -$789K | -$1.99M |
| **Free Cash Flow** | -$33.49M | -$24.02M |
| **Investing Cash Flow** | -$11.79M | $22.26M |
| Share Repurchases | -$1.45M | $0 |
| **Financing Cash Flow** | $124.6M | $185K |
| **Net Change in Cash** | $80.09M | $419K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$24.25M | -$19.86M | -$13.82M | -$12.55M | -$9.82M | -$8.68M | -$8.82M |
| Depreciation & Amortization | $280K | $341K | $318K | $217K | $137K | $135K | $124K |
| Stock-Based Compensation | $2.31M | $2.08M | $1.68M | $922K | $932K | $587K | $345K |
| Change in Payables | $1.51M | $764K | $953K | $1.02M | -$1.29M | $1.19M | -$372K |
| **Operating Cash Flow** | -$16.02M | -$14.84M | -$13.54M | -$9.34M | -$8.84M | -$6.33M | -$8.20M |
| Capital Expenditure | -$2.46M | -$1.93M | -$676K | -$421K | -$152K | -$52K | -$164K |
| **Free Cash Flow** | -$18.48M | -$16.77M | -$14.22M | -$9.76M | -$8.99M | -$6.38M | -$8.37M |
| **Investing Cash Flow** | $1.54M | -$933K | -$1.67M | $574K | -$12.15M | -$52K | -$164K |
| **Financing Cash Flow** | $27K | $13K | $157.8M | -$888K | -$236K | $75.61M | $50.10M |
| **Net Change in Cash** | -$14.46M | -$15.76M | $142.5M | -$9.65M | -$21.23M | $69.24M | $41.73M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Return on Assets (ROA) | -34.4% | -125.1% |
| Current Ratio | 12.67x | 2.23x |
| Quick Ratio | 11.23x | 2.09x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -33.5% | -24.1% | -17.9% | -- | -- | -- | -- |
| Return on Assets (ROA) | -31.1% | -23.0% | -17.4% | -34.4% | -- | -- | -- |
| Current Ratio | 15.24x | 25.06x | 38.00x | 12.67x | -- | -- | -- |
| Quick Ratio | 14.60x | 23.65x | 35.83x | 11.23x | -- | -- | -- |
| Debt to Equity | 0.01x | 0.01x | 0.01x | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
